Dozens of Congressional lawmakers are urging the FDA to crack down on the booming market for knockoff weight loss drugs amid mounting concerns over their potential safety risks, Bloomberg’s Madison Muller reports. On Friday, a group of more than 80 bipartisan lawmakers asked the agency to stop counterfeit and copycat versions of GLP-1 drugs like Novo Nordisk’s (NVO) Wegovy and Eli Lilly’s (LLY) Zepbound from flooding the market, suggesting issuing warning letters and better monitoring non-compliant online retailers and compounding pharmacies that sell the medicines. “We support the bi-partisan call for the FDA to crack down on counterfeit and illegally sold weight-loss drugs,” said a spokesperson for Hims & Hers Health (HIMS).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Novo Nordisk’s Stock Soars Amid Strategic Moves
- HIMS Lawsuit Alert! Hims & Hers Faces Class Action Lawsuit After Wegovy Scandal
- Avidity, Phathom mentioned as potential takeout targets at Needham
- Hims & Hers (HIMS) Faces Legal Storm Post Novo Nordisk Breakup
- Eli Lilly’s Weight-Loss Drug Faces New Competition from China